Main content

Will 340B Cuts Affect Clinical Outcomes?

Chris Hudson, who serves as a managing director and healthcare industry lead at the consultancy firm Dacarba LLC, says it’s too soon to tell whether the reimbursements will adequately compensate some hospitals. “Hospitals are faced with declining reimbursements and increasing costs, which is placing continued pressures on operational excellence and clinical outcomes.”


CLICK HERE TO READ THE FULL DRUG TOPICS ARTICLE